Micro-needle patch containing notoginsenoside

By using microneedle patches of Panax notoginseng, Chicken Blood Vine and Huangbai Charcoal extract after tooth extraction, the problems of large suture tension and healing in wound care after tooth extraction were solved, and effective hemostasis, anti-inflammatory and bone generation were achieved. Provides better therapeutic effects.

CN118924670APending Publication Date: 2024-11-12ZHEJIANG CHINESE MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410964908.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing wound care technology after tooth extraction has problems such as high suture tension, easy thread knot slipping, difficulty in effectively stopping hemostatic, anti-inflammatory and healing, and lacks the osteogenic effect of Chinese medicine microneedle patch.

Method used

A microneedle patch containing Panax notoginseng, Chicken Blood Vine and Huangbai Charcoal extract was developed to form a microneedle body by photocrosslinking the hydrogel complex and the base surface of hyaluronic acid to promote bone formation and healing.

Benefits of technology

Significantly improve the healing process of tooth extraction wounds, inhibit inflammation, promote bone formation, improve the proliferation and differentiation of bone marrow stem cells, reduce the risk of wound exposure, and provide better bioavailability and therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924670A_ABST
    Figure CN118924670A_ABST
Patent Text Reader

Abstract

The invention relates to a microneedle patch, the microneedle patch comprises a patch substrate surface and a drug-containing hydrogel microneedle, the drug-containing hydrogel microneedle comprises a traditional Chinese medicine extract, a hydrogel matrix solution and a cross-linking agent, and the traditional Chinese medicine extract comprises a pseudo-ginseng extract, a caulis spatholobi extract and a cortex phellodendri charcoal extract in a mass ratio of (1-5): (1-5): (1-5). The hydrogel compound containing the compound traditional Chinese medicine extract is selected as the content of the needle body of the microneedle patch, sustained-release drug delivery is performed under the dual technical advantages of the microneedle and the photo-crosslinking hydrogel, gingival soft tissue inflammation progress near a tooth extraction wound is inhibited, bone conduction and osteogenesis below are promoted, and bone marrow stem cells are collected for proliferation and differentiation. The substrate of the microneedle patch provided by the invention adopts a hyaluronic acid component, has good water retention effect and biocompatibility, and can seal wounds while reducing tension compared with traditional sutures and wound patches.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicines, and in particular to a microneedle patch containing notoginseng saponin. Background Art

[0002] In recent years, with the spread and development of implant technology, implant restoration has been increasingly widely used in the treatment of patients after tooth extraction. A large number of literatures show that the key to the success of implantation in patients lies in the care of the wound of tooth extraction patients. Rapid closure of the wound and reduction of wound exposure area can avoid complications such as wound dehiscence, leakage of contents, and secondary inflammation. At present, the wound is mainly tightened and fixed by physical means of sutures in clinical practice, but the effect is unsatisfactory, and only physical methods will be affected by complex environmental factors in the individual's mouth. In addition, there are still some problems in wound control after tooth extraction, such as high tension of traditional sutures, easy slippage of knots, and wound exposure. Only physical methods to close the window are not conducive to hemostasis, anti-inflammation, healing of soft tissues in tooth extraction wounds, and underlying osteogenesis.

[0003] Microneedles are a new type of transdermal drug delivery technology, which consists of an array of micron-sized sharp needles. After piercing the oral mucosa, they will leave micropores on the skin, thereby increasing the permeability of drug molecules on the skin. Compared with oral and injection administration, microneedle administration can avoid drug degradation caused by various digestive enzymes and chemical factors in the gastrointestinal tract and the first-pass effect of the liver. It is especially suitable for local lesions such as skin infections and chronic wounds. It can avoid the toxic side effects caused by systemic administration and reduce local blood drug concentration fluctuations. Compared with traditional wound dressings, microneedles can penetrate the microbial membranes and eschars formed during the healing process, allowing the active ingredients to enter healthy cells and diffuse to take effect. In addition, microneedle preparations have good adhesion and the drug molecules carried can painlessly penetrate the epidermis to the dermis, increase the concentration and bioavailability of therapeutic drugs on the wound surface, and significantly improve the treatment effect.

[0004] Huangbai charcoal mainly activates the endogenous coagulation pathway, increases platelet content, increases TXB2 content to promote platelet aggregation, promotes fibrin production, increases PAI-1 content to inhibit the fibrinolytic system to exert hemostatic effects. Millettia reticulata is a Chinese medicine for promoting blood circulation and removing blood stasis. It tastes bitter and sweet, is warm in nature, and enters the liver and kidney meridians. It has the effects of promoting blood circulation, regulating menstruation and relieving pain, and relaxing muscles and activating collaterals. Panax notoginseng is one of the precious Chinese medicinal materials recognized by traditional Chinese medicine in my country. It has a slight smell, a bitter and sweet taste, is warm in nature, and enters the liver and stomach meridians. It is traditionally used for bleeding symptoms of blood stasis and blood not flowing through the meridians. It is also the first choice for treating traumatic injuries, blood stasis and swelling and pain. It has the effects of removing blood stasis and stopping bleeding, promoting blood circulation and relieving pain. These effects are closely related to promoting osteogenesis, and can provide a new bone repair model for clinical treatment of bone healing. In clinical application, it is a multi-system targeted drug that can regulate the differentiation of multiple adult stem cells.

[0005] So far, there are no reports on Chinese herbal microneedle patches that have an osteogenic effect on patients after tooth extraction. Summary of the invention

[0006] To solve the above technical problems, the present invention includes the following aspects:

[0007] The first aspect of the present invention provides a microneedle patch, which comprises a patch base surface and drug-containing hydrogel microneedles, wherein the drug-containing hydrogel microneedles comprise a traditional Chinese medicine extract, a hydrogel matrix solution and a cross-linking agent, and the traditional Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron chinense charcoal extract.

[0008] Preferably, the Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of (1-5): (1-5): (1-5). More preferably, the Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of (1-3): (1-3): (1-3). Further preferably, the Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of (2-3): (2-3): (1-2). Further preferably, the Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of 3:2:1, or comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of 2:2:2, or comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of 2:2:1, or comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron charcoal extract in a mass ratio of 2:3:1. Most preferably, the Chinese herbal extract comprises Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 2:2:1.

[0009] Preferably, in terms of mass percentage, the content of Panax notoginseng extract in the hydrogel matrix is ​​1-5%, the content of Millettia spatholobi extract is 1-5%, and the content of Phellodendron chinense charcoal extract is 1-5%. More preferably, the content of Panax notoginseng extract in the hydrogel matrix is ​​1-3%, the content of Millettia spatholobi extract is 1-3%, and the content of Phellodendron chinense charcoal extract is 1-3%. Further preferably, the content of Panax notoginseng extract in the hydrogel matrix is ​​2%, the content of Millettia spatholobi extract is 2%, and the content of Phellodendron chinense charcoal extract is 1%.

[0010] Preferably, the extraction method of the Panax notoginseng extract is as follows: extract the Panax notoginseng root powder with 95% ethanol by heating and refluxing for 1-2 times, and then cool the filtrate, concentrate it, and dry it to obtain the extract.

[0011] More preferably, the extraction method of the Panax notoginseng extract is as follows: weigh Panax notoginseng root powder with a particle size of 60 mesh, put it into a flask, add 95% ethanol 10 times the weight of the medicinal material to the flask, heat and reflux in a constant temperature water bath for extraction; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the filter residue, and combine the filtrates of the two extractions; rotary evaporate the combined filtrate in a rotary evaporator to obtain a concentrated solution; place the concentrated solution in an oven and dry it to constant weight to obtain the Panax notoginseng extract.

[0012] Further preferably, 50 g of Panax notoginseng root powder with a particle size of 60 mesh is accurately weighed and put into a flask, 500 mL of 95% ethanol is added to the flask, and the mixture is heated to reflux in a constant temperature water bath at 80°C for extraction for 3 hours; the extract is cooled to room temperature, filtered and the filtrate is collected; the above extraction steps are repeated on the residue, and the filtrates from the two extractions are combined; the combined filtrate is evaporated at 50°C in a rotary evaporator to obtain a concentrated solution; the concentrated solution is placed in an oven at 60°C and dried to constant weight to obtain a Panax notoginseng extract.

[0013] Preferably, the preparation method of the Millettia spatholobi extract is as follows: Millettia spatholobi powder is extracted by heating and refluxing with 70% ethanol, and the filtrate is cooled, concentrated, and dried to obtain the extract.

[0014] More preferably, the preparation method of the Millettia spatholobi extract is as follows: weigh Millettia spatholobi powder with a particle size of 60 mesh and put it into a flask; add 70% ethanol 10 times the weight of the medicinal material to the flask, heat and reflux in a constant temperature water bath for extraction; cool the extract to room temperature, filter and collect the filtrate; transfer the filtrate to a rotary evaporator for rotary evaporation to obtain a concentrated solution; place the concentrated solution in an oven to dry, thereby obtaining the Millettia spatholobi extract.

[0015] Further preferably, the preparation method of the Millettia spatholobi extract is as follows: accurately weigh 100g of Millettia spatholobi powder with a particle size of 60 mesh and put it into a flask. Add 1000mL of 70% ethanol to the flask, heat and reflux in a 75°C constant temperature water bath for 4 hours. Cool the extract to room temperature, filter and collect the filtrate. Transfer the filtrate to a rotary evaporator and rotary evaporate at 45°C to obtain a concentrated solution. Place the concentrated solution in an oven at 50°C and dry it for 12 hours to obtain the Millettia spatholobi extract.

[0016] Preferably, the preparation method of the Phellodendron charcoal extract is as follows: extract the Phellodendron charcoal powder by heating it with deionized water for 1-2 times, and then cool the filtrate, concentrate it, and dry it to obtain the extract.

[0017] More preferably, the preparation method of the Phellodendron charcoal extract is as follows: weigh Phellodendron charcoal powder with a particle size of 60 mesh and put it into a flask; add deionized water 8 times the weight of the medicinal material to the flask, and heat and extract in a constant temperature water bath; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue, and combine the filtrates from the two extractions; rotary evaporate the combined filtrate in a rotary evaporator to obtain a concentrated solution; place the concentrated solution in an oven and dry it to constant weight to obtain the Phellodendron charcoal extract.

[0018] Further preferably, the preparation method of the Phellodendron charcoal extract is as follows: accurately weigh 100 g of Phellodendron charcoal powder with a particle size of 60 mesh, and put it into a flask; add 800 mL of deionized water to the flask, and heat and extract in a constant temperature water bath at 100°C for 6 hours; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue, and combine the filtrates from the two extractions; evaporate the combined filtrate at 45°C in a rotary evaporator to obtain a concentrated solution; dry the concentrated solution in an oven at 60°C to constant weight to obtain the Phellodendron charcoal extract.

[0019] Preferably, the hydrogel matrix solution is a polyethylene glycol aqueous solution.

[0020] Preferably, the concentration of the hydrogel matrix solution is 10-30% W / V. More preferably, the concentration of the hydrogel matrix solution is 15-25% W / V. Further preferably, the concentration of the hydrogel matrix solution is 20% W / V.

[0021] Preferably, the crosslinking agent is methyl methacrylate.

[0022] Preferably, the concentration of methyl methacrylate is 0.1-5% W / V, more preferably, the concentration of methyl methacrylate is 0.5-3% W / V, and further preferably, the concentration of methyl methacrylate is 1% W / V.

[0023] Preferably, the patch substrate is made of an aqueous solution of hyaluronic acid.

[0024] Preferably, the mass ratio of the hyaluronic acid to deionized water is 1:(1-10). More preferably, the mass ratio of the hyaluronic acid to deionized water is 1:(3-5). Further preferably, the mass ratio of the hyaluronic acid to deionized water is 1:4.

[0025] Preferably, the bottom surface of the drug-containing hydrogel microneedle is circular, the diameter of the needle bottom is 300 μm, and the needle height is 800 μm.

[0026] The second aspect of the present invention provides a method for preparing the above-mentioned microneedle patch, which comprises the following steps:

[0027] (1) Preparation of Chinese herbal medicine extracts: extracting Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract from Panax notoginseng, Phellodendron amurense and Millettia spatholobi respectively;

[0028] (2) Preparation of hydrogel matrix solution: dissolving polyethylene glycol in deionized water to prepare a hydrogel matrix solution;

[0029] (3) Preparation of drug-containing hydrogel solution: adding the Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract prepared in step (1) to the hydrogel matrix solution obtained in step (2), and then adding methyl methacrylate as a cross-linking agent, mixing thoroughly, centrifuging and degassing;

[0030] (4) Introducing into a mold and photocrosslinking: injecting the hydrogel solution prepared in step (3) onto a silicone mold, vibrating it sufficiently, placing it in a vacuum chamber for treatment, and irradiating the solution with an ultraviolet lamp;

[0031] (5) Hydrogel molding: After irradiation, the gel in the mold was left to stand at room temperature for at least 1 hour until cross-linking was complete;

[0032] (6) Preparing a microneedle patch substrate solution: adding hyaluronic acid and deionized water into a centrifuge tube, stirring until completely dissolved, centrifuging and degassing to obtain a microneedle patch substrate solution;

[0033] (7) Making a microneedle patch: drip the microneedle patch substrate solution prepared in step (6) onto the hydrogel microneedles of the silicone mold in step (5), place the mold in a vacuum chamber for treatment, and then cure at room temperature and demold to obtain the product.

[0034] Preferably, the preparation method of the Panax notoginseng extract in step (1) is as follows: extracting the Panax notoginseng root powder with 95% ethanol by heating and refluxing for 1-2 times, cooling the filtrate, concentrating it, and drying it.

[0035] More preferably, the extraction method of Panax notoginseng extract in step (1) is as follows: weigh Panax notoginseng root powder with a particle size of 60 mesh, put it into a flask, add 95% ethanol in an amount of 10 times the weight of the medicinal material to the flask, and heat and reflux in a constant temperature water bath for extraction; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue, and combine the filtrates from the two extractions; rotary evaporate the combined filtrate in a rotary evaporator to obtain a concentrated solution; and dry the concentrated solution in an oven to constant weight to obtain Panax notoginseng extract.

[0036] Further preferably, the extraction method of Panax notoginseng extract in the step (1) is as follows: accurately weigh 50g of Panax notoginseng root powder with a particle size of 60 mesh, put it into a flask, add 500mL of 95% ethanol to the flask, heat and reflux in a constant temperature water bath at 80°C for extraction for 3 hours; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue, and combine the filtrates of the two extractions; evaporate the combined filtrate at 50°C in a rotary evaporator to obtain a concentrated solution; place the concentrated solution in an oven at 60°C and dry it to constant weight to obtain Panax notoginseng extract.

[0037] Preferably, the preparation method of the Millettia spatholobi extract in step (1) is as follows: extracting Millettia spatholobi powder by heating and refluxing with 70% ethanol, cooling the filtrate, concentrating it, and drying it to obtain the extract.

[0038] More preferably, the preparation method of the Millettia spatholobi extract in the step (1) is as follows: weigh Millettia spatholobi powder with a particle size of 60 mesh and put it into a flask; add 70% ethanol in an amount of 10 times the weight of the medicinal material to the flask, and heat and reflux in a constant temperature water bath for extraction; cool the extract to room temperature, filter and collect the filtrate; transfer the filtrate to a rotary evaporator for rotary evaporation to obtain a concentrated solution; and dry the concentrated solution in an oven to obtain the Millettia spatholobi extract.

[0039] Further preferably, the preparation method of the Millettia spatholobi extract in the step (1) is as follows: accurately weigh 100g of Millettia spatholobi powder with a particle size of 60 mesh and put it into a flask. Add 1000mL of 70% ethanol to the flask, heat and reflux in a 75°C constant temperature water bath for 4 hours. Cool the extract to room temperature, filter and collect the filtrate. Transfer the filtrate to a rotary evaporator and rotary evaporate at 45°C to obtain a concentrated solution. Place the concentrated solution in an oven at 50°C and dry for 12 hours to obtain the Millettia spatholobi extract.

[0040] Preferably, the preparation method of the Phellodendron charcoal extract in step (1) is as follows: extracting the Phellodendron charcoal powder by heating it with deionized water for 1-2 times, cooling the filtrate, concentrating it, and drying it to obtain the extract.

[0041] More preferably, the preparation method of the Phellodendron charcoal extract in step (1) is as follows: weigh Phellodendron charcoal powder with a particle size of 60 mesh and put it into a flask; add deionized water 8 times the weight of the medicinal material to the flask, and heat and extract in a constant temperature water bath; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue, and combine the filtrates from the two extractions; rotary evaporate the combined filtrate in a rotary evaporator to obtain a concentrated solution; place the concentrated solution in an oven and dry it to constant weight to obtain the Phellodendron charcoal extract.

[0042] Further preferably, the preparation method of the Phellodendron charcoal extract in the step (1) is as follows: accurately weigh 100 g of Phellodendron charcoal powder with a particle size of 60 mesh, and put it into a flask; add 800 mL of deionized water to the flask, and heat and extract in a constant temperature water bath at 100°C for 6 hours; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue, and combine the filtrates from the two extractions; evaporate the combined filtrate in a rotary evaporator at 45°C to obtain a concentrated solution; place the concentrated solution in an oven at 60°C and dry it to constant weight to obtain the Phellodendron charcoal extract.

[0043] Preferably, the concentration of the hydrogel matrix solution in step (2) is 10-30% W / V. More preferably, the concentration of the hydrogel matrix solution in step (2) is 15-25% W / V. Further preferably, the concentration of the hydrogel matrix solution in step (2) is 20% W / V.

[0044] Preferably, the mass ratio of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract added to the hydrogel matrix solution in step (3) is (1-5): (1-5): (1-5). More preferably, the mass ratio of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract added to the hydrogel matrix solution in step (3) is (1-3): (1-3): (1-3). Further preferably, the mass ratio of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract added to the hydrogel matrix solution in step (3) is 3:2:1, or the mass ratio is 2:2:2, or the mass ratio is 2:2:1, or the mass ratio is 2:3:1.

[0045] Preferably, in the step (3), the content of Panax notoginseng extract in the hydrogel matrix is ​​1-5%, the content of Millettia spatholobi extract is 1-5%, and the content of Phellodendron chinense charcoal extract is 1-5%. More preferably, in the step (3), the content of Panax notoginseng extract in the hydrogel matrix is ​​1-3%, the content of Millettia spatholobi extract is 1-3%, and the content of Phellodendron chinense charcoal extract is 1-3%. Further preferably, in the step (3), the content of Panax notoginseng extract in the hydrogel matrix is ​​2%, the content of Millettia spatholobi extract is 2%, and the content of Phellodendron chinense charcoal extract is 1%.

[0046] Preferably, 0.1-5% W / V of methyl methacrylate is added in step (3). More preferably, 0.5-3% W / V of methyl methacrylate is added in step (3). Further preferably, 1% W / V of methyl methacrylate is added in step (3).

[0047] Preferably, in step (3), the mixture is centrifuged at 500 r for 3 min in a centrifuge.

[0048] Preferably, the material of the silicone mold in step (4) is polydimethylsiloxane.

[0049] Preferably, the microneedle patch mold used in step (4) is square in shape with a side length of 16.7 mm, 20*20 needles per sheet, a needle spacing of 700 μm, a needle base diameter of 300 μm, and a needle height of 800 μm.

[0050] Preferably, in step (4), the silicone mold is placed in a 0.1 MPa vacuum chamber for 15 minutes.

[0051] Preferably, in step (4), the solution is irradiated with an ultraviolet lamp having a wavelength of 365 nm for 20 minutes.

[0052] Preferably, the mass ratio of hyaluronic acid to deionized water in step (6) is 1:(1-10). More preferably, the mass ratio of hyaluronic acid to deionized water in step (6) is 1:(3-5). Further preferably, the mass ratio of hyaluronic acid to deionized water in step (6) is 1:4.

[0053] Preferably, in step (6), centrifuge is used for centrifugation at 500r for 2 minutes.

[0054] Preferably, in step (7), the treatment is performed in a 0.1 MPa vacuum chamber for 15 minutes.

[0055] The third aspect of the present invention provides the use of the above-mentioned microneedle patch in the preparation of a drug for promoting osteogenesis.

[0056] Preferably, the promoting osteogenesis is promoting alveolar bone formation.

[0057] The method of using the microneedle patch of the present invention is as follows: immediately after tooth extraction, use interrupted suture or continuous suture to close the tooth extraction wound, trim the microneedle patch to a suitable size (the wide section after trimming is adapted to the length of the dental arch in the edentulous area), one end of the long section is attached to the vestibule groove, and the other end is attached to the hard palate (from the alveolar ridge to two-thirds of the palatal suture). Each microneedle patch is square, with a size of 16.7mm*16.7mm, and the volume of a single microneedle is 0.05652mm 3 The total volume of microneedles in a single microneedle patch is 22.608mm 3 , drug loading density is 0.1mg / mm 3 The total single loading amount is 2.2608 mg.

[0058] The technical effects produced by the present invention are:

[0059] In the present invention, notoginseng saponins, millet catechins and phellodendron charcoal extracts are firstly prepared into a hydrogel complex by photocrosslinking as the contents of the microneedle body, and hyaluronic acid is prepared into a microneedle veneer substrate by room temperature curing. Compared with conventional site preservation techniques, the method of the present invention has the following obvious advantages:

[0060] 1. The substrate of the microneedle patch of the present invention is made of hyaluronic acid, which is the main component of the extracellular matrix and has good water retention and biocompatibility. Compared with traditional sutures and wound dressings, it can seal the wound while reducing tension.

[0061] 2. The needle body of the microneedle patch of the present invention is made of a hydrogel complex of Panax notoginseng extract (including notoginseng saponins), Millettia spatholobi extract (including Millettia spatholobi catechins), and Phellodendron chinense charcoal extract. The drug is delivered in a sustained-release manner with the dual technical advantages of microneedles and photo-cross-linked hydrogels, which inhibits the progression of inflammation of the gingival soft tissue near the tooth extraction wound, promotes bone conduction and bone formation below, and recruits bone marrow stem cells for proliferation and differentiation. BRIEF DESCRIPTION OF THE DRAWINGS

[0062] Figure 1 The results of the cell proliferation test of the Chinese herbal extract compositions with different ratios of the present invention;

[0063] Figure 2 It is a live / dead cell staining diagram of the Chinese medicine extract composition with different ratios of the present invention;

[0064] Figure 3 It is the ALP immunohistochemical result of the contents of the drug-containing microneedles with different ratios of Chinese herbal medicine extracts of the present invention;

[0065] Figure 4 This is a HE staining picture of a patient who used the microneedle patch clinically after trephination to obtain bone;

[0066] Figure 5 This is a graph showing the expression results of CD31 positive cells in patients using the microneedle patch of the present invention clinically. DETAILED DESCRIPTION

[0067] The present invention is further described below in conjunction with examples, but the embodiments of the present invention are not limited thereto. The experimental methods used in the following examples are conventional methods unless otherwise specified.

[0068] Example 1: Chinese medicine microneedle patch P1 of the present invention

[0069] 1. Preparation of microneedle contents

[0070] (1) Preparation of Chinese medicine extracts: Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract were extracted from Panax notoginseng, Phellodendron amurense and Millettia spatholobi, respectively, and the specific methods are as follows:

[0071] (i) Preparation of Panax notoginseng extract: Accurately weigh 50 g of Panax notoginseng root powder with a particle size of 60 mesh, put it into a round-bottom flask with a capacity of 1000 mL, add 500 mL of 95% ethanol to the flask, heat and reflux in a constant temperature water bath at 80°C for 3 hours. Cool the extract to room temperature, filter and collect the filtrate. Repeat the above extraction steps on the residue, and combine the filtrates from the two extractions. Rotate the combined filtrate in a rotary evaporator at 50°C to obtain a concentrated solution. Place the concentrated solution in an oven at 60°C and dry it to constant weight to obtain Panax notoginseng extract.

[0072] (ii) Preparation of Millettia spatholobi extract: Accurately weigh 100 g of Millettia spatholobi powder with a particle size of 60 mesh and put it into a flask. Add 1000 mL of 70% ethanol to the flask and heat it under reflux in a constant temperature water bath at 75°C for 4 hours. Cool the extract to room temperature, filter and collect the filtrate. Transfer the filtrate to a rotary evaporator and rotary evaporate at 45°C to obtain a concentrated solution. Place the concentrated solution in an oven and dry it at 50°C for 12 hours to obtain the Millettia spatholobi extract.

[0073] (iii) Preparation of Phellodendron charcoal extract: Accurately weigh 100 g of Phellodendron charcoal powder with a particle size of 60 mesh and put it into a flask; add 800 mL of deionized water to the flask and heat it in a constant temperature water bath at 100°C for 6 hours; cool the extract to room temperature, filter and collect the filtrate; repeat the above extraction steps on the residue and combine the filtrates from the two extractions; evaporate the combined filtrate in a rotary evaporator at 45°C to obtain a concentrated solution; dry the concentrated solution in an oven at 60°C to constant weight to obtain the Phellodendron charcoal extract.

[0074] (2) Preparation of hydrogel matrix solution: Polyethylene glycol (PEG) was dissolved in deionized water to prepare a 20% W / V hydrogel matrix solution.

[0075] (3) Preparation of drug-containing hydrogel solution: The notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract prepared in step (1) were added to the hydrogel matrix solution obtained in step (2) at a mass ratio of 2:2:1, wherein the notoginseng extract content in the hydrogel matrix was 2%, the Millettia spatholobi extract content was 2%, and the Phellodendron chinense charcoal extract content was 1% by mass. 1% W / V methyl methacrylate (MMA) was then added as a cross-linking agent. A magnetic stirrer was used to mix thoroughly to ensure that the components were evenly dispersed, and then centrifuged at 500r for 3 minutes in a centrifuge to remove bubbles.

[0076] (4) Introducing into the mold and photocrosslinking: Use a micropipette to absorb the hydrogel solution prepared in step (3) and slowly and evenly inject it onto the dried polydimethylsiloxane silicone mold to ensure that each microneedle mold needle body is fully filled. Each microneedle needle body is 1000 μm high, with a round bottom and an area of ​​0.60 cm2 The mold was gently tapped or shaken using a laboratory vibrator, and the mold filled with hydrogel was placed in a 0.1 MPa vacuum chamber for 15 minutes to facilitate the hydrogel solution to fully fill the mold. The solution was irradiated with a 365 nm wavelength UV lamp for 20 minutes.

[0077] (5) Hydrogel molding: After irradiation, the gel in the mold was left to stand at room temperature for at least 1 hour until cross-linking was complete.

[0078] 2. Preparation of microneedle patch substrate solution

[0079] Hyaluronic acid (HA) and deionized water were added into a centrifuge tube at a mass ratio of 1:4, stirred until completely dissolved, centrifuged at 500 r for 2 min in a centrifuge to remove bubbles, and a patch base surface solution was obtained.

[0080] 3. Make microneedle veneer

[0081] Use a micropipette to absorb the microneedle patch substrate solution prepared in step 2, drop it on the microneedle unit of the silicone mold made of polydimethylsiloxane, and treat it in a 0.1MPa vacuum chamber for 15 minutes. Place the mold at room temperature until it is completely cured, and demold carefully (if necessary, the mold can be slightly heated before demolding or a demolding agent can be used to reduce demolding resistance), and the traditional Chinese medicine microneedle patch P1 of the present invention is obtained.

[0082] Example 2: Chinese medicine microneedle patch P2 of the present invention

[0083] The ratio of each Chinese medicine extract was adjusted, and the "hydrogel matrix containing Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 2:2:1" in Example 1 was replaced with "hydrogel matrix containing Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 3:2:1", and the total weight percentage of the three extracts remained unchanged, that is, a total of 5%. The remaining components and preparation method steps are the same as in Example 1, and the Chinese medicine microneedle patch P2 of the present invention is obtained.

[0084] Example 3: Chinese medicine microneedle patch P3 of the present invention

[0085] The ratio of each Chinese medicine extract was adjusted, and the "hydrogel matrix containing Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 2:2:1" in Example 1 was replaced by "hydrogel matrix containing Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 2:3:1", and the total weight percentage of the three extracts remained unchanged, that is, a total of 5%, and the remaining components and preparation method steps were the same as in Example 1, to obtain the Chinese medicine microneedle patch P3 of the present invention.

[0086] Example 4: Chinese medicine microneedle patch P4 of the present invention

[0087] The ratio of each Chinese medicine extract was adjusted, and the "hydrogel matrix containing Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 2:2:1" in Example 1 was replaced by "hydrogel matrix containing Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract in a mass ratio of 2:2:2", and the total weight percentage of the three extracts remained unchanged, that is, a total of 5%, and the remaining components and preparation method steps were the same as in Example 1, to obtain the Chinese medicine microneedle patch P4 of the present invention.

[0088] Test Example 1: Cell proliferation test of the Chinese medicine composition of the present invention

[0089] 1. Test methods

[0090] In this study, the CCK-8 method was used to evaluate the effects of different ratios of Panax notoginseng extract, Millettia spatholobi extract, and Phellodendron chinense charcoal extract on L929 mouse fibroblast cell line. L929 cells were evenly inoculated into 96-well plates, with 5×10 cells per well. 3 cells and culture at 37°C and 5% CO 2 The cells were cultured in an environment of 24 hours to promote cell attachment. The Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract prepared in Example 1 were all prepared into a 0.5 mg / mL solution using DMSO solvent. In test groups 1-4, mixed solutions of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract with a mass ratio of 3:2:1, 2:2:2, 2:2:1 and 2:3:1 were added to L929 cells, respectively. The added volume per well of each test group was 20 μL, and the total weight of the drug per well was 10 μg (taking the mixed solution of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract with a mass ratio of 3:2:1 as an example, the total weight of the three extracts was 10 μg, of which Panax notoginseng extract was 5 μg, Millettia spatholobi extract was 3.33 μg, and Phellodendron chinense charcoal extract was 1.67 μg. The total weight of the three extracts in the remaining test groups was 10 μg). DMEM high-glucose medium was added to the negative control group. The cells continued to be cultured under the same conditions for 1 day and 4 days. At each time point, CCK-8 reagent was added to each well, and the absorbance (OD value) was measured at a wavelength of 450 nm using a microplate reader after incubation for 2 hours to evaluate the effects of different ratios of Chinese herbal extracts on cell proliferation.

[0091] 2. Test results

[0092] The cell compatibility of four groups of extracts with different ratios and a negative control group was evaluated by using the CCK-8 method. Figure 1), the optical density (OD) values ​​of the negative control group and the four experimental groups gradually increased with the extension of culture time, which indicated that the number of cells in the negative control group and the experimental group increased with time. In addition, the OD values ​​of the four experimental groups were generally higher than those of the negative control group, especially on the fourth day of culture, the OD values ​​of the four experimental groups were significantly higher than those of the negative control group, with statistically significant differences (p<0.05).

[0093] The above test results show that the combination of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense carbon extract has good biocompatibility, and the Chinese medicine composition has a promoting effect on cell proliferation, and this promoting effect is more significant over time. In particular, the composition with a mass ratio of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense carbon extract of 2:2:1 performs best in promoting cell proliferation.

[0094] Test Example 2: Cytotoxicity test of the Chinese medicine composition of the present invention

[0095] 1. Test methods

[0096] This test example uses live / dead cell staining technology to evaluate the cytotoxicity of different ratios of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract mixtures on L929 cell line. The Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract prepared in Example 1 were all prepared into a 0.5 mg / mL solution with DMSO solvent. L929 cells were evenly seeded on a 48-well culture plate, and 1×10 4 Cells were cultured in duplicate wells for each treatment group. The cells were cultured at 37°C and 5% CO 2 After culturing for 24 hours under the conditions of , the mixed solutions of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract with a mass ratio of 3:2:1, 2:2:2, 2:2:1 and 2:3:1 were added to L929 cells in test groups 1-4, and the culture was continued for 1 day and 4 days. The added volume of each well in each test group was 100 μL, and the total weight of the drug in each well was 50 μg (taking the mixed solution of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract with a mass ratio of 3:2:1 as an example, the total weight of the three extracts was 50 μg, including 25 μg of Panax notoginseng extract, 16.7 μg of Millettia spatholobi extract and 8.3 μg of Phellodendron chinense charcoal extract. The total weight of the three extracts in the remaining test groups was 50 μg). After the culture cycle, the culture medium was removed and washed three times with PBS. Then the cells were stained with a live / dead cell staining working solution composed of Calcein-AM and PI (ratio 2:5:1000, dissolved in PBS) for 20 minutes. The cells were washed again three times with PBS to remove residual dye, and then an inverted fluorescence microscope was used to observe and record cell activity and death, and to evaluate the effects of different ratios of Chinese herbal extracts on cytotoxicity.

[0097] 2. Test results

[0098] In this test example, live cells show bright green fluorescence due to the absorption of Calcein-AM, which can pass through the intact cell membrane. Dead cells emit red fluorescence due to the penetration of propidium iodide (PI). Figure 2 As shown in the figure, on the first day of the experiment, L929 cells in all test groups were successfully attached, and most of them showed a typical spindle morphology. On the fourth day of the experiment, the number of cells in each test group increased significantly, and most of the cells showed a spindle morphology. In particular, in the test groups with a mass ratio of Chinese herbal extracts of 2:2:1 and 3:2:1, the cell aggregation phenomenon was more significant, and almost no dead cells were observed, indicating that the test groups using the above-mentioned Chinese herbal extract ratios had good cell compatibility and low cytotoxicity.

[0099] Experimental Example 3: Osteogenesis effect of the drug-containing microneedle contents of the present invention on the rabbit tibial bone defect model

[0100] 1. Test methods

[0101] 1.1. Preparation of rabbit tibial bone defect model

[0102] Twenty-four adult female New Zealand rabbits, 15 weeks old, weighing (2.5±0.5) kg, were randomly divided into four experimental groups, 6 in each group. 2-3% isoflurane inhalation was used to maintain intraoperative anesthesia, and 2% lidocaine hydrochloride was used at a ratio of 1:80,000 to induce local anesthesia. The left and right tibiae of the rabbits were disinfected, shaved, and skin was prepared. The upper epithelial layer, muscle layer, and periosteum were separated by flaps to expose the surgical field of the medial tibiae on both sides. Two cylindrical defects with a diameter of 2.2 mm and a height of about 6 mm were made on one side, 5 mm apart from each other, and were made using dental pioneer drills with diameters of 1.0 mm, 1.8 mm, and 2.2 mm, respectively, at a rotation speed of 1500 rpm and rinsed with cold saline.

[0103] 1.2 Implantation of drug-containing microneedle contents

[0104] The needle hydrogel contents 1-4 with different ratios of Chinese medicine extracts were prepared by referring to the method of Examples 1-4 (the mass ratios of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract were 2:2:1, 3:2:1, 2:3:1 and 2:2:2, respectively). The New Zealand rabbits in the four test groups respectively pressed the same weight of the above needle hydrogel contents 1-4 into a mass and implanted them into the bone defect area, and then sutured the incision layer by layer. The total content of Chinese medicine extracts contained in the hydrogel contents implanted in each test group was 0.5g (taking the mixture solution of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract with a mass ratio of 3:2:1 as an example, the total weight of the three extracts was 0.5g, of which Panax notoginseng extract was 0.25g, Millettia spatholobi extract was 0.1667g, and Phellodendron chinense charcoal extract was 0.0833g; the total weight of the three extracts in the other test groups was 0.5g). Penicillin G (240,000UI) was injected intramuscularly for three days after surgery to prevent infection. Raise rabbits in separate cages as usual, and regularly observe and record the health status of the rabbits and the healing of their wounds.

[0105] 1.3 Tissue sample testing

[0106] Alkaline phosphatase (ALP) is a key enzyme in osteoblast differentiation and bone mineralization, and its increased activity is an early marker in the bone formation process. High ALP activity indicates that osteoblasts are actively producing bone matrix and are ready for the mineralization process. This test case uses the following standardized process to process and analyze hard tissue samples to ensure high-quality tissue sections for subsequent alkaline phosphatase (ALP) staining and microscopic analysis:

[0107] (1) Sample collection and fixation: Hard tissue samples were collected on days 14 and 42, washed five times with phosphate buffered saline (PBS), and then fixed with 4% paraformaldehyde. The samples were then washed five times with deionized water to remove excess fixative.

[0108] (2) Cutting and dehydration: The fixed samples were fixed with formalin for 24 hours, and then the excess tissue was removed with a scalpel in a fume hood and the target tissue was flattened. The samples were placed in a dehydration box for marking and then subjected to a series of alcohol dehydration (75% alcohol for 4 hours, 85% alcohol for 2 hours, 90% alcohol for 2 hours, 95% alcohol for 1 hour, and anhydrous ethanol I and II for 30 minutes each).

[0109] (3) Transparent treatment: The sample is first immersed in a mixed solution of anhydrous ethanol and xylene for 5-10 minutes, and then transferred to xylene I and xylene II for 5-10 minutes each. The purpose is to replace anhydrous ethanol for better paraffin impregnation.

[0110] (4) Paraffin impregnation and embedding: The processed tissues are placed in paraffin I, II, and III at 65°C in turn, and then embedded in paraffin using an embedding machine. During the embedding process, the melted paraffin is first poured into the embedding frame, and then the tissue is positioned and marked according to the needs. After completion, it is cooled and solidified at -20°C.

[0111] (5) Sectioning and mounting: The embedded wax block was cut into 4 μm thick sections, flattened on 40°C water, picked up with a slide and dried. The sections were soaked in xylene twice for 20 minutes each, and in anhydrous ethanol twice for 5 minutes each, followed by treatment with 75% alcohol for 5 minutes, and finally washed with deionized water.

[0112] (6) Staining and microscopic observation: ALP staining was performed according to the instructions. After staining, the slides were dehydrated, transparentized, and sealed with a neutral resin. An inverted fluorescence microscope was used to observe and collect images for analysis.

[0113] 2. Test results

[0114] In this experimental example, p-nitrophenyl phosphate (pNPP) was used as a substrate for alkaline phosphatase (ALP). Under alkaline conditions, pNPP reacted with ALP to generate yellow p-nitrophenol (pNP). Using this reaction, the activity of ALP can be quantitatively analyzed by measuring the area ratio of the yellow product. In the experiment, ImageJ software was used to process and quantify the area of ​​the yellow product to quantitatively evaluate the activity of ALP. Under the same exposure time, the darker the yellow color and the more areas, the more ALP is secreted by mBMSCs in the bone defect area, that is, the higher the degree of osteogenic differentiation. Compared with other experimental groups, when the mass ratio of Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract was 2:2:1, the surface had deeper and wider areas of yellow insoluble matter, indicating that this ratio has a greater effect on promoting the osteogenic differentiation of mBMSCs (see Figure 3 ).

[0115] Test Example 4: Clinical trial results of the drug-containing microneedle patch of the present invention

[0116] 1. Test methods

[0117] This trial collected data from patients who visited the outpatient clinic of the Affiliated Stomatological Hospital of Zhejiang Chinese Medical University from April 2022 to March 2024, and recruited a total of 81 adult patients who needed to extract a single anterior or posterior tooth. The participants were randomly divided into two groups: 44 cases in Group A (microneedle patch administration group receiving treatment, including 26 males and 18 females); 37 cases in Group B (blank control group that did not receive any wound treatment, including 17 males and 20 females). This study has been approved by the Ethics Committee of the Affiliated Stomatological Hospital of Zhejiang Chinese Medical University, and all participating patients have been informed of the details of the study in advance and signed informed consent.

[0118] Inclusion criteria: (1) generally healthy, without underlying diseases such as diabetes, hypertension, osteoporosis, etc.; (2) having a premolar or molar that cannot be preserved due to caries, root fracture, or periodontitis (chronic inflammation can be removed by scraping or rinsing the tooth extraction wound), with 1 / 3-2 / 3 of the buccal or lingual alveolar ridge of the affected tooth absorbed, and the remaining three bone walls intact with a remaining height of at least ≥5 mm; (3) at least one adjacent tooth preserved, with at least 2 / 3 of its root surrounded by bone and not loose; (4) having good oral hygiene and not smoking; (5) having good compliance, voluntarily participating in the study and signing the informed consent form.

[0119] Exclusion criteria: (1) severe bone defects that do not meet the above conditions; (2) twisting or malposition of adjacent teeth anterior and posterior to the affected tooth; (3) patients with severe periodontal disease who have not received periodontal system treatment; (4) patients with a history of head and neck radiotherapy within 5 years; (5) patients who are pregnant, breastfeeding, or planning to become pregnant; (6) patients who have been taking nonsteroidal, bisphosphonates, corticosteroids, or other drugs that affect bone metabolism and bone healing for a long time; and (7) other conditions that are contraindications to tooth extraction.

[0120] Immediately after tooth extraction, interrupted sutures or continuous sutures are used to close the extraction wound, and the microneedle patch is trimmed to an appropriate size (the wide section after trimming is adapted to the length of the dental arch in the edentulous area), with one end of the long section attached to the vestibule groove and the other end attached to the hard palate (two-thirds of the way from the alveolar ridge to the mid-palatal suture).

[0121] The subjects were randomly divided into group A or group B, and the subjects were informed by envelope. The patients underwent minimally invasive extraction of the affected teeth under local anesthesia, and the visible inflammatory tissue was removed and repeatedly rinsed with saline. According to the grouping, the microneedle patch prepared in Example 1 was given or not given a microneedle patch. Group A was treated with one drug-containing microneedle patch (each microneedle patch was square, with a size of 16.7 mm*16.7 mm, and a single microneedle had a volume of 0.05652 mm 3 The total volume of microneedles in a single microneedle patch is 22.608mm 3 , drug loading density is 0.1mg / mm 3, the total drug loading was 2.2608 mg per time), and group B was a blank control group that did not receive any wound treatment. Patients in both groups took oral antibiotics for 3 days after surgery, and wound healing was observed 2 weeks later. Implant surgery was performed 18 weeks after tooth extraction, and during the operation, a hollow bone trephine with a diameter of 3 to 5 mm was selected according to the width of the patient's bone. At a lower speed (300 to 500 rpm), the direction and position of the implantation socket were accurately prepared until it was about 1 mm away from the floor of the maxillary sinus. When the cortical bone of the sinus floor was felt to be hard, drilling was stopped. Subsequently, a small piece of cylindrical bone was removed from the prepared position by gently shaking with hemostatic forceps and wrapped with sterile saline gauze. In particular, when the bone height is very low (3 mm and below) or the patient's bone is very porous (DⅣ class), you can choose not to remove the cylindrical bone block, but directly punch it.

[0122] After the specimens were fixed for 24-72 hours, they were dehydrated and embedded, and made into 5μm slices. The slices were dewaxed by adding xylene I and II successively, and stained with hematoxylin for 10 minutes until purple-red appeared, and then washed with water; treated with 1% hydrochloric acid for 30 seconds, washed with water, and blue was observed in weak alkaline aqueous solution, and washed with water; eosin staining was performed, and ethanol was used for dehydration. Xylene I and II were transparent, and neutral gum was dropped on the slide, and the cover slip was covered and dried naturally. The slices were observed under a low-power microscope, and the bone harvest rate was calculated.

[0123] The expression ratio of CD31-positive cells was observed under an optical microscope and photographed. Based on the Weidner microvessel counting method, CD31-positive cells (i.e. single endothelial cells or clustered endothelial cells stained brown-yellow) were counted as blood vessels. Regardless of whether there was lumen formation, if they were clearly separated from the surrounding blood vessels and tissues, they were considered as microvessels that could be counted, but blood vessels with thicker muscle layers, meninges, and endothelial cells stained with ependyma were not included. The film was observed and photographed under a 200× field of view, and 3 non-repeated fields of view were randomly selected to calculate the number of blood vessels in each field of view, and the average value of the three fields of view was taken to represent the microvessel count of the slice.

[0124] 2. Test results

[0125] Representative sample micrographs of the microneedle patch group and the blank control group of the present invention are shown in FIG. Figure 4 (Scale bar: 50μm) As shown in the figure, the new bone in the microneedle patch group is scattered in the coronal plane and the middle part of the specimen, and collagen fibers are formed on or between the new bone cords. Under the HE staining microscope, a large amount of new bone formation can be seen in the microneedle patch group, and it is relatively mature and dense, and a large amount of fibrous connective tissue can be seen around it.

[0126] CD31 can specifically mark newborn endothelial cells. In this experiment, we used immunohistochemistry to detect the expression of CD31 to reflect the microvessel density in the bone column removed by bone drilling in clinical patients. Typical samples are as follows: Figure 5 As shown (scale: 50μm). According to statistical analysis, the microvessel density in the microneedle patch group was (44.97±3.12), which was higher than that in the blank control group (28.60±9.30), and the difference between the two experimental groups was statistically significant (P<0.01).

[0127] Although specific embodiments of the present invention have been described, it will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the scope or spirit of the present invention. Therefore, the present invention is intended to cover all such changes and modifications that fall within the scope of the appended claims and their equivalents.

Claims

1. A microneedle patch, characterized in that: The microneedle patch comprises a patch base surface and drug-containing hydrogel microneedles, the drug-containing hydrogel microneedles comprise traditional Chinese medicine extracts, a hydrogel matrix solution and a cross-linking agent, and the traditional Chinese medicine extracts comprise notoginseng extracts, millettia spatholobi extracts and phellodendron charcoal extracts.

2. The microneedle patch according to claim 1, characterized in that The Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron chinense charcoal extract in a mass ratio of (1-5):(1-5):(1-5).

3. The microneedle patch according to claim 1, characterized in that: The Chinese medicine extract comprises a Panax notoginseng extract, a Millettia spatholobi extract and a Phellodendron chinense charcoal extract in a mass ratio of (1-3):(1-3):(1-3).

4. The microneedle patch according to claim 1, characterized in that: The hydrogel matrix solution is a polyethylene glycol aqueous solution.

5. The microneedle patch according to claim 1, characterized in that: The crosslinking agent is methyl methacrylate.

6. The microneedle patch according to claim 1, characterized in that: The patch base surface is made of an aqueous solution of hyaluronic acid.

7. The microneedle patch according to claim 1, characterized in that: The bottom surface of the drug-containing hydrogel microneedle is circular, the diameter of the needle bottom is 300 μm, and the needle height is 800 μm.

8. The method for preparing the microneedle patch according to any one of claims 1 to 7, characterized in that: The following steps are involved: (1) Preparation of Chinese herbal medicine extracts: extracting Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract from Panax notoginseng, Phellodendron amurense and Millettia spatholobi respectively; (2) Preparation of hydrogel matrix solution: dissolving polyethylene glycol in deionized water to prepare a hydrogel matrix solution; (3) Preparation of drug-containing hydrogel solution: adding the Panax notoginseng extract, Millettia spatholobi extract and Phellodendron chinense charcoal extract prepared in step (1) to the hydrogel matrix solution obtained in step (2), and then adding methyl methacrylate as a cross-linking agent, mixing thoroughly, centrifuging and degassing; (4) Introducing into a mold and photocrosslinking: injecting the hydrogel solution prepared in step (3) onto a silicone mold, vibrating it sufficiently, placing it in a vacuum chamber for treatment, and irradiating the solution with an ultraviolet lamp; (5) Hydrogel molding: After irradiation, the gel in the mold was left to stand at room temperature for at least 1 hour until cross-linking was complete; (6) Preparing a microneedle patch substrate solution: adding hyaluronic acid and deionized water into a centrifuge tube, stirring until completely dissolved, centrifuging and degassing to obtain a microneedle patch substrate solution; (7) Making a microneedle patch: drip the microneedle patch substrate solution prepared in step (6) onto the hydrogel microneedles of the silicone mold in step (5), place the mold in a vacuum chamber for treatment, and then cure at room temperature and demold to obtain the product.

9. Use of the microneedle patch according to any one of claims 1 to 7 in the preparation of a drug for promoting osteogenesis.

10. The use according to claim 9, characterized in that: The promoting osteogenesis is promoting alveolar bone formation.